Related Experiment Video
Updated: Aug 8, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Engineered macrophages with IL-10-TLR9 signal switch receptors for reprogramming tumor microenvironment and enhancing
Sijie Wang1,2, Owais Ahmad2, Kexin Shui2
1Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
None:
Chimeric antigen receptor (CAR) T cell immunotherapy has achieved remarkable success in hematologic malignancies, prompting the exploration of CAR strategies in solid tumors. Here, we developed a CAR-like signal-switching receptor-macrophage (SR CAR-M) that recognizes IL-10, a major immunosuppressive cytokine enriched in solid tumors, and converts this inhibitory signal into a pro-inflammatory activation through the Toll-like receptor 9 (TLR9) intracellular signaling pathway. SR CAR-Ms effectively blocked IL-10-mediated STAT3 phosphorylation while activating TLR9 downstream signaling, including nuclear translocation of nuclear factor-κB and upregulation of IRF1, thereby adopting an M1-like phenotype with enhanced phagocytic capacity and tumor cytotoxicity. Domain-deletion controls demonstrated that both IL-10 binding and TLR9 signaling are indispensable. In addition, SR CAR-Ms promoted dendritic cell maturation, enhanced T cell proliferation and effector function, and prevented T cell exhaustion. In an orthotopic 4T1 breast cancer model, infused SR CAR-Ms selectively accumulated in tumors, depleted local IL-10 while inducing inflammatory cytokine production, suppressed tumor growth, and prolonged survival without systemic toxicity. The signal-switching mechanism was validated in primary bone marrow-derived macrophages and human monocyte-derived macrophages, supporting the translational applicability. Further enhancement was achieved by engineering dual-function SRPα CAR-Ms secreting anti-PD-L1 antibodies, which outperformed either SR CAR-M or anti-PD-L1 monotherapy. The SR CAR-M platform transforms an immunosuppressive cytokine into a location-specific activation trigger, simultaneously depleting the inhibitory signal and remodeling the tumor microenvironment. This signal-switching paradigm offers a versatile approach for treating solid malignancies that are resistant to conventional immunotherapies.
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy
